Immune thrombocytopenia and Fc receptor-mediated phagocyte function.

Abstract:

:The response to intravenous immunoglobulin treatment (IVIG) is thought, in part, to be due to blockade of Fc receptor for IgG in the mononuclear phagocyte system (MPS). We have studied this by measuring splenic clearance of heat-damaged and IgG antibody-coated red cells in immune thrombocytopenic patients receiving IVIG. Clearance of heat-damaged red blood cells (HDRBC) labelled with technetium 99MM was measured in eight patients before and after a 5-day infusion of IVIG. In six of the eight there was an enhanced clearance of HDRBC post IVIG. Clearance studies were performed in eight rhesus-D-positive patients using autologous red cells coated with anti-D and labelled with 99MTc. The time taken for the radioactivity at 3 min to fall to 50% (T1/2) was calculated. The T1/2 increased in seven of the eight patients from a mean of 78.5 min to 137.1 min, a prolongation of 74.6%. In addition, we have examined the effect of IVIG on Fc-mediated phagocytosis by neutrophils. Platelet phagocytosis by patients' neutrophils was measured using opsonized autologous platelets in nine patients. There was a marked reduction in platelet phagocytosis as measured by formazan production in all patients at day 4-5 when compared with the preinfusion value, and in half of these this reduction was still evident at further studies, 1 week after the end of the infusion period. The platelet count rose in parallel with the fall in platelet phagocytic ability of the neutrophils, reaching a peak at 7 days post infusion, and fell with the recovery of phagocytic function in weeks 2 and 3. These findings suggest that IVIG has a marked effect on Fc-mediated phagocytosis.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Newland AC,Macey MG

doi

10.1007/BF01698483

subject

Has Abstract

pub_date

1994-08-01 00:00:00

pages

61-7

issue

2

eissn

0939-5555

issn

1432-0584

journal_volume

69

pub_type

杂志文章
  • Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL).

    abstract::A 40-year-old patient with low-grade B-NHL developed a generalized macular-papular rash following the first cycle of fludarabine treatment which progressed to a complete epidermal necrolysis following the second cycle. Clinical symptoms and the results of the direct and indirect immunofluorescence were consistent with...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050347

    authors: Braess J,Reich K,Willert S,Strutz F,Neumann C,Hiddemann W,Wörmann B

    更新日期:1997-11-01 00:00:00

  • Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III.

    abstract::We tested two Fc gamma receptor I (Fc gamma RI); six Fc gamma RII; and six Fc gamma RIII-specific monoclonal antibodies (mAb) for their capacity to inhibit monocyte and polymorphonuclear granulocyte (PMN) immune phagocytosis which is mediated by Fc gamma R. We used human red blood cells (rbc) coated with hIgG1 or mIgG...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050249

    authors: Flesch BK,Achtert G,Neppert J

    更新日期:1997-01-01 00:00:00

  • Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.

    abstract::Relapse remains one of the major obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) even after allogeneic hematopoietic stem cell transplantation. The persistence of leukemia-propagating cells (LPCs) may lead to the recurrence of Ph+ALL. Using a xenograft assay, LPCs enrichment in the ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-018-3253-5

    authors: Zhao HY,Song Y,Cao XN,Qin YZ,Lai YY,Jiang H,Jiang Q,Huang XJ,Kong Y

    更新日期:2018-05-01 00:00:00

  • Trends in quality of non-Hodgkin's lymphoma care: is it getting better?

    abstract::This study outlines trends in quality of delivered non-Hodgkin's lymphoma (NHL) care in the Netherlands between 2007 and 2011 and to what extend this was influenced by the national Visible Care program, which aimed at increasing transparency by providing insight into the quality of healthcare. We analyzed data collect...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s00277-015-2340-0

    authors: Stienen JJ,Ottevanger PB,Wennekes L,van de Schans SA,Dekker HM,van der Maazen RW,van Krieken JH,Blijlevens NM,Hermens RP,PEARL study group.

    更新日期:2015-07-01 00:00:00

  • Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).

    abstract::The objective of this study was to evaluate the efficacy and safety of rituximab in the treatment of patients with idiopathic thrombocytopenic purpura (ITP). A prospective study was performed at Mubarak Al-Kabeer University Hospital involving the use of rituximab in 14 patients who had previously been treated with ste...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-008-0574-9

    authors: Alasfoor K,Alrasheed M,Alsayegh F,Mousa SA

    更新日期:2009-03-01 00:00:00

  • The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.

    abstract::Currently, the diagnosis of acute graft-versus-host disease (aGVHD) is mainly based on clinical symptoms and biopsy results. This study was designed to further explore new no noninvasive biomarkers for aGVHD prediction/diagnosis. We profiled miRNAs in serum pools from patients with aGVHD (grades II-IV) (n = 9) and non...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-016-2781-0

    authors: Zhang C,Bai N,Huang W,Zhang P,Luo Y,Men S,Wen T,Tong H,Wang S,Tian YP

    更新日期:2016-10-01 00:00:00

  • High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.

    abstract::This retrospective single-center analysis studied the impact of the conditioning and the graft-versus-host disease (GVHD) prophylaxis on outcome in unselected patients allografted for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) secondary to documented prior CMML. A total of 44 patients (med...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-020-03952-4

    authors: Radujkovic A,Hegenbart U,Müller-Tidow C,Herfarth K,Dreger P,Luft T

    更新日期:2020-04-01 00:00:00

  • Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

    abstract::Although retreatment with alemtuzumab in relapsing B-cell chronic lymphocytic leukemia (CLL) may be beneficial, there has thus far been no thorough analysis available on this topic. Data were collected from 30 chemotherapy-pretreated patients with progressive CLL who had received alemtuzumab twice in consecutive, dist...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-011-1192-5

    authors: Fiegl M,Falkner F,Steurer M,Zojer N,Hopfinger G,Haslbauer F,Winder G,Voskova D,Andel J,Lang A,Brychtova Y,Mayer J,Greil R,Gastl G,Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.,Czech Leuk

    更新日期:2011-09-01 00:00:00

  • Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple).

    abstract::The incidence of multiple myeloma (MM) has increased in the last 20 years, particularly in middle and low-middle income countries. Access to diagnostic and prognostic tests and the availability of effective care is highly variable globally. Latin America represents 10% of the world population, distributed in countries...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s00277-020-03983-x

    authors: Riva E,Schütz N,Peña C,Ruiz-Argüelles G,Hopkins CR,Bove V,Villano F,Andino L,Suárez L,Martínez H,Navarro J,López-Vidal H,Da Costa O,Pineda MR,Rubio Y,Ramirez J,Choque J,Fantl D

    更新日期:2020-05-01 00:00:00

  • Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients.

    abstract::To investigate the problem of allogeneic bone marrow transplantation (allo-BMT) for advanced stage patients, we retrospectively analyzed 24 consecutive patients who underwent allo-BMT in the non-remission stage. Twenty-four patients (19 males and 5 females) with acute leukemia, chronic myelogenous leukemia, and malign...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-002-0506-z

    authors: Tabata M,Satake A,Okura N,Yamazaki Y,Toda A,Nishioka K,Tanaka H,Chin M,Itsukuma T,Yamaguchi M,Misawa M,Kai S,Hara H

    更新日期:2002-10-01 00:00:00

  • Morphologic and phenotypic changes of the leukemic cells in a case of marginal zone B-cell lymphoma.

    abstract::A particular case of marginal zone B-cell lymphoma (MZBCL) presenting with leukemic lymphocytes is reported. In the present observation, the leukemic cells not only displayed a remarkable morphological fluctuation but also had an unusual phenotype, changing with time. These phenotypic features, which have been functio...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050274

    authors: Dargent JL,Delville JP,Kornreich A,Pradier O,Cochaux P,Velu T,Capel P,Feremans W,Neve P

    更新日期:1997-03-01 00:00:00

  • Correlation study between osteoporosis and hematopoiesis in the context of adjuvant chemotherapy for breast cancer.

    abstract::This retrospective study attempts to establish if a correlation exists between osteoporosis and hematopoiesis before and after adjuvant chemotherapy in the context of non-metastatic breast cancer. Osteoporosis is interpreted both as a direct marker of osteoblastic decline and as an indirect marker of increased bone ma...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-017-3184-6

    authors: Schyrr F,Wolfer A,Pasquier J,Nicoulaz AL,Lamy O,Naveiras O

    更新日期:2018-02-01 00:00:00

  • IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.

    abstract:PURPOSE:The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma. PATIENTS AND METHODS:The study was performed as an open-label non-randomized multicenter phase-II trial and included patients older than 18 years of age wi...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002770000163

    authors: Feuring-Buske M,Kneba M,Unterhalt M,Engert A,Gramatzki M,Hiller E,Trümper L,Brugger W,Ostermann H,Atzpodien J,Hallek M,Aulitzky E,Hiddemann W

    更新日期:2000-09-01 00:00:00

  • Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein.

    abstract::Recently, it was shown that glycoproteins with N-glycans close to the NH(2) terminus can directly enter the calnexin/calreticulin cycle and bypass BiP binding. This should allow efficient secretion of glycoproteins such as factor VIII (FVIII) whose secretion is negatively affected by BiP interaction. Examination of th...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-007-0380-9

    authors: Srour MA,Grupp J,Aburubaiha Z,Albert T,Brondke H,Oldenburg J,Schwaab R

    更新日期:2008-02-01 00:00:00

  • Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells.

    abstract::FLT3 and its ligand (FL) are one of the regulators of normal hematopoiesis. Ligand-independent activation of FLT3 occurs in about 30% of acute myeloid leukemia cases and is one goal for selectively targeted therapies. However, the function of FLT3/FL in the regulation of non-malignant immature hematopoietic cells is p...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-008-0605-6

    authors: Weisel KC,Yildirim S,Schweikle E,Kanz L,Möhle R

    更新日期:2009-03-01 00:00:00

  • Two novel factor X gene mutations in a Chinese family with factor X deficiency.

    abstract::We report a factor X (FX)-deficient Chinese family with two novel FX gene (F10) mutations. Two sibling probands had a bleeding tendency since childhood. Both had very low FX:C (<0.01 IU/ml) and FX:Ag (5-6%) levels and were heterozygous for two novel F10 mutations, a 2-bp GC deletion involving nucleotides 33 and 34, le...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-003-0803-1

    authors: Au WY,Lam CC,Cheung WC,Kwong YL

    更新日期:2004-05-01 00:00:00

  • Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.

    abstract::Polo-like kinase 2 (SNK/PLK2), a transcriptional target for wild-type p53 and is hypermethylated in a high percentage of multiple myeloma and B cell lymphomas patients. Given these data, we sought to study the methylation status of the specific gene in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1193-4

    authors: Benetatos L,Dasoula A,Hatzimichael E,Syed N,Voukelatou M,Dranitsaris G,Bourantas KL,Crook T

    更新日期:2011-09-01 00:00:00

  • Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.

    abstract::Since July 2017, different generic imatinib formulations have been introduced in Italy for the treatment of patients with chronic myeloid leukemia (CML). We analyzed 168 chronic phase CML patients treated with branded imatinib for a median of 12 years (range 1-16) at a single institution who switched to a single gener...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-020-04096-1

    authors: Scalzulli E,Colafigli G,Latagliata R,Pepe S,Diverio D,Stocchi F,Di Prima A,Efficace F,Martelli M,Foà R,Breccia M

    更新日期:2020-12-01 00:00:00

  • Genotyping of 22 blood group antigen polymorphisms and establishing a national recipient registry in the Korean population.

    abstract::It is often difficult for standard blood banks in Korea to supply adequate amounts of blood for patients with rare phenotype. Moreover, the definition of a blood in need is ambiguous, and much remains to be learned. In this study, we determined the prevalence of various red blood cell (RBC) antigens from a donor viewp...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2645-7

    authors: Hong YJ,Chung Y,Hwang SM,Park JS,Kwon JR,Choi YS,Kim JN,Lee DH,Kwon SY,Cho NS,Song EY,Park KU,Song J,Han KS

    更新日期:2016-05-01 00:00:00

  • Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.

    abstract::Ixazomib, the first oral proteasome inhibitor (PI), has been approved for the treatment of relapsed refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, based on the TOURMALINE-MM1 phase 3 trial, which demonstrated the efficacy and safety of this all-oral triplet, compared with lenali...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-020-03985-9

    authors: Cohen YC,Magen H,Lavi N,Gatt ME,Chubar E,Horowitz N,Kreiniz N,Tadmor T,Trestman S,Vitkon R,Rouvio O,Shvetz O,Shaulov A,Ziv-Baran T,Avivi I

    更新日期:2020-06-01 00:00:00

  • Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment.

    abstract::Blastic transformation of essential thrombocythemia (ET) preceded by chemotherapy is occasionally described in the literature. In ET as well as in other myeloproliferative disorders the leukemogenic effect of alkylating agents and (32)P is well established, and recent reports also indicate a certain leukemogenic effec...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050007

    authors: Andersson PO,Ridell B,Wadenvik H,Kutti J

    更新日期:2000-01-01 00:00:00

  • Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.

    abstract::In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00277-016-2638-6

    authors: Gratwohl A,Iacobelli S,Bootsman N,van Biezen A,Baldomero H,Arcese W,Arnold R,Bron D,Cordonnier C,Ernst P,Ferrant A,Frassoni F,Gahrton G,Richard C,Kolb HJ,Link H,Niederwieser D,Ruutu T,Schattenberg A,Schmitz N,Torr

    更新日期:2016-05-01 00:00:00

  • The presence of CD28-negative T cells in a patient with multicentric Castleman's disease.

    abstract::We found increased numbers of CD28-negative T cells in a patient with multicentric Castleman's disease (MCD), who also had significantly decreased interleukin-2 (IL-2) production and impaired T-cell proliferation. The presence of CD28-negative T cells may be indicative of a functional T-cell defect in MCD. ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050228

    authors: Ishiyama T,Koike M,Kakimoto T,Akimoto Y,Tsuruoka N

    更新日期:1996-10-01 00:00:00

  • Hereditary protein C deficiency in Indian patients with venous thrombosis.

    abstract::Approximately, 4-11 % of the patients with idiopathic venous thrombosis (VT) show protein C (PC) deficiency. The molecular pathology of PC deficiency was analyzed in 102 patients; 98 healthy controls were also studied to assess the association of various polymorphisms with reduced PC levels. PROC gene mutations were d...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-012-1483-5

    authors: Pai N,Ghosh K,Shetty S

    更新日期:2012-09-01 00:00:00

  • Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma.

    abstract::We analyzed the prognostic factors for a successful mobilization and peripheral blood stem cell collection in a series of 57 consecutive patients with multiple myeloma (MM); a new scoring system to predict an adequate mobilization in this subset of patients was also constructed. A total of 221 aphereses were performed...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770100351

    authors: Perea G,Sureda A,Martino R,Altés A,Martínez C,Cabezudo E,Amill B,Martín-Henao GA,González Y,Muñoz L,Peyret M,Brunet S,Sierra J

    更新日期:2001-10-01 00:00:00

  • Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL.

    abstract::Therapy-induced autoimmunity may mediate the destruction of cancer cells. Previous studies have demonstrated that presence of autoimmune thyroid disorder is associated with favorable outcome in patients with solid cancer. Patients with diffuse large B cell lymphoma (DLBCL) who achieved complete response on positron em...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-015-2311-5

    authors: Song MK,Chung JS,Kim SJ,Kim SS,Shin HJ

    更新日期:2015-06-01 00:00:00

  • Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis.

    abstract::There is increasing evidence for the role of chronic antigenic stimulation (CS) in the development of cancer. Clinical data, however, are rare as is the information on outcome. In this study, the occurrence of chronic infections (CI) and autoimmune diseases (AI) in patients with malignant lymphoma at diagnosis was ass...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1178-3

    authors: Vanura K,Späth F,Gleiss A,Le T,Porpaczy E,Skrabs C,Hauswirth A,Fleiss K,Wessely F,Gaiger A,Müllauer L,Jäger U

    更新日期:2011-08-01 00:00:00

  • sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-α therapy.

    abstract::Interferon-α (IFNα) was the first effective drug therapy for hairy cell leukemia (HCL). Nowadays, it is used as an alternative treatment in selected patients. Due to unlimited treatment time, monitoring and early prediction of response are important. Moreover, IFNα is used in the therapy of chronic hepatitis C, where ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-017-2943-8

    authors: Jud S,Goede JS,Senn O,Spanaus K,Manz MG,Benz R

    更新日期:2017-05-01 00:00:00

  • Effects of thrombopoietin on megakaryocyte colony formation from leukemic cells at diagnosis and from marrow cells after induction chemotherapy for acute leukemias.

    abstract::We have studied the effects of recombinant human thrombopoietin (TPO, mpl ligand) on the megakaryocyte colony formation from control human bone marrow cells, human leukemia cells at diagnosis, and human bone marrow cells after induction chemotherapy for acute leukemias. In the control human bone marrow cells from four...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050408

    authors: Liang DC,Shih LY,Kuo MC,Chen SH,Liu HC,Shimosaka A

    更新日期:1998-07-01 00:00:00

  • Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine.

    abstract::Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is an atypical lympho-proliferative disorder with borderline features that often constitute a diagnostic challenge for the hematopathologist and a therapeutic dilemma for the treating clinician. Morphologically, the involved lymph nodes in this disorder are...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050244

    authors: Sallah AS,Bernard S

    更新日期:1996-12-01 00:00:00